Publication date: Jul 11, 2023
Lithium is regarded as the first-line treatment for bipolar disorder (BD), a severe and disabling mental health disorder that affects about 1% of the population worldwide. Nevertheless, lithium is not consistently effective, with only 30% of patients showing a favorable response to treatment. To provide personalized treatment options for bipolar patients, it is essential to identify prediction biomarkers such as polygenic scores. In this study, we developed a polygenic score for lithium treatment response (Li) in patients with BD. To gain further insights into lithium’s possible molecular mechanism of action, we performed a genome-wide gene-based analysis. Using polygenic score modeling, via methods incorporating Bayesian regression and continuous shrinkage priors, Li was developed in the International Consortium of Lithium Genetics cohort (ConLiGen: N = 2367) and replicated in the combined PsyCourse (N = 89) and BipoLife (N = 102) studies. The associations of Li and lithium treatment response – defined in a continuous ALDA scale and a categorical outcome (good response vs. poor response) were tested using regression models, each adjusted for the covariates: age, sex, and the first four genetic principal components. Statistical significance was determined at P
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | bipolar disorder |
| disease | MESH | mental disorder |
| drug | DRUGBANK | Acetylcholine |
| disease | MESH | mania |
| disease | MESH | comorbidity |
| disease | MESH | suicide |
| disease | MESH | schizophrenia |
| drug | DRUGBANK | Coenzyme M |
| pathway | REACTOME | Translation |